iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/34765482/
The metabolic effects of multi-trace elements on parenteral nutrition for critically ill pediatric patients: a randomized controlled trial and metabolomic research - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;10(10):2579-2593.
doi: 10.21037/tp-21-456.

The metabolic effects of multi-trace elements on parenteral nutrition for critically ill pediatric patients: a randomized controlled trial and metabolomic research

Qingti Tan #  1 , Yu Wang #  2   3 , Guoying Zhang #  1 , Bin Lu  1 , Tao Wang  1 , Tao Tao  1 , He Wang #  4 , Hua Jiang  2   3 , Wei Chen  5
Affiliations

The metabolic effects of multi-trace elements on parenteral nutrition for critically ill pediatric patients: a randomized controlled trial and metabolomic research

Qingti Tan et al. Transl Pediatr. 2021 Oct.

Abstract

Background: We investigated the efficacy and metabolic dose-effect of multi-trace element injection I [MTEI-(I)] for severe pediatric patients via a parallel, randomized control study.

Methods: The inclusion criteria were as follows: (I) patients who required parenteral nutrition (PN) due to various diseases, and were expected to receive PN for >5 days; (II) patients aged <18 years; (III) patients with no serious cardiac, hepatic, renal, or pulmonary dysfunction; and (IV) patients with an established central venous pathway. Enrolled patients were randomly assigned into two groups using sequentially numbered, sealed, opaque envelopes: Group A (low-dose group) received MTEI-(I) at 1 mL/kg/d, and Group B (high-dose group) received MTEI-(I) at 2 mL/kg/d, up to a maximum dose of 15 mL/d. The concentrations of manganese (Mn), copper (Cu), zinc (Zn), and selenium (Se) were detected. The following indexes were measured after 5 days of treatment (T5): β-oxidation of very-long-chain fatty acids, arginine and proline metabolism, pentose phosphate metabolism, ketone body metabolism, citric acid cycle, purine metabolism, caffeine metabolism, and pyruvate metabolism. The participants, care givers, and data analysis staff were blinded to the group assignment.

Results: Overall, at T5, Mn and Cu levels were decreased, while Zn and Se levels were increased. The increase of Zn levels (A: 0.170±0.479 vs. B: 0.193±0.900) and decrease of Cu levels (A: -0.240±0.382 vs. B: -0.373±0.465) of patients in Group B (n=22) were significantly higher than those in Group A (n=18). At T5, the β-oxidation of very-long-chain fatty acids, arginine and proline metabolism, pentose phosphate metabolism, ketone body metabolism, citric acid cycle, purine metabolism, caffeine metabolism, and pyruvate metabolism were variably decreased (P<0.05) in Group B compared to Group A.

Conclusions: Our results suggested that the high-dose administration of MTEI-(I) is safe for severe pediatric patients, and may alleviate inflammation and antioxidation, relieve hyperactivity caused by stress, and improve tissues-based hypoxia and renal function.

Trial registration: Chinese Clinical Trial Registry ChiCTR2100052198.

Keywords: Multi-trace element injection I [MTEI-(I)]; intensive care; metabolomics; parenteral nutrition (PN); pediatric.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tp-21-456). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Patient recruitment into groups.
Figure 2
Figure 2
PLS-DA of patients at T0 and T5 (A: 1 mL/kg; B: 2 mL/kg). PLS-DA, partial least squares-discriminant analysis.
Figure 3
Figure 3
PLS-DA VIP values of chemical shifts between T0 and T5 (A: 1 mL/kg; B: 2 mL/kg). PLS-DA, partial least squares-discriminant analysis; VIP, variable importance in the projection.
Figure 4
Figure 4
PLS-DA for patients at T5 in Group A and Group B. PLS-DA, partial least squares-discriminant analysis.
Figure 5
Figure 5
VIP chemical shift values between T5 metabolic differences in Group A and Group B. VIP, variable importance in the projection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jacobs A, Verlinden I, Vanhorebeek I, et al. Early Supplemental Parenteral Nutrition in Critically Ill Children: An Update. J Clin Med 2019;8:830. 10.3390/jcm8060830 - DOI - PMC - PubMed
    1. Pediatric Collaborative Group, Society of Parenteral and Enteral Nutrition, Chinese Medical Association . Guidelines for pediatric clinical application of enteral and parenteral nutritional support in China. Zhonghua Er Ke Za Zhi 2010;48:436-41. - PubMed
    1. Tabor E. Current Status of Multi-Trace Element Products for Parenteral Nutrition in the United States. Nutr Clin Pract 2019;34:487-8. 10.1002/ncp.10317 - DOI - PubMed
    1. Marino LV, Valla FV, Beattie RM, et al. Micronutrient status during paediatric critical illness: A scoping review. Clin Nutr 2020;39:3571-93. 10.1016/j.clnu.2020.04.015 - DOI - PMC - PubMed
    1. Shenkin A. Micronutrients in health and disease. Postgrad Med J 2006;82:559-67. 10.1136/pgmj.2006.047670 - DOI - PMC - PubMed